Marken presented a case study at the Cell & Gene Therapy Europe Conference in Barcelona, which focused on a global, multi-centered cell-based therapy trial involving nearly 1,000 patients in over 20 countries. The trial requires shipments of bio-hazardous material derived from patient samples, which are transported in liquid nitrogen containers but must reach the manufacturing site within 28 hours of the patient visit.  The logistics of preparing the samples, transporting them across country...